XTX Topco Ltd Boosts Stock Position in CryoPort, Inc. $CYRX

XTX Topco Ltd boosted its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 463.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,485 shares of the company’s stock after buying an additional 60,440 shares during the period. XTX Topco Ltd’s holdings in CryoPort were worth $548,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in shares of CryoPort by 299.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock worth $27,000 after acquiring an additional 2,729 shares during the last quarter. ProShare Advisors LLC purchased a new stake in CryoPort during the 2nd quarter valued at about $75,000. Avanza Fonder AB increased its stake in CryoPort by 31.4% during the 2nd quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after purchasing an additional 2,601 shares in the last quarter. Savant Capital LLC purchased a new position in CryoPort in the second quarter worth about $93,000. Finally, Creative Planning purchased a new position in CryoPort in the second quarter worth about $96,000. 92.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CYRX shares. Leerink Partners raised shares of CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Wednesday, August 6th. KeyCorp upgraded shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price on the stock in a research note on Wednesday, August 6th. BTIG Research lifted their price target on shares of CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Needham & Company LLC boosted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Leerink Partnrs upgraded shares of CryoPort from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.83.

Insider Activity at CryoPort

In other news, Director Robert J. Hariri sold 25,000 shares of CryoPort stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the transaction, the director directly owned 51,275 shares of the company’s stock, valued at $497,880.25. The trade was a 32.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.10% of the stock is owned by company insiders.

CryoPort Trading Up 2.2%

Shares of CryoPort stock opened at $9.41 on Thursday. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $11.44. The company’s fifty day simple moving average is $9.39 and its 200-day simple moving average is $8.33. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The stock has a market capitalization of $471.15 million, a PE ratio of 8.04 and a beta of 1.51.

CryoPort (NASDAQ:CYRX) last announced its earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.The company had revenue of $44.23 million for the quarter, compared to analysts’ expectations of $41.22 million. As a group, equities analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.